Real World Evidence Study to Assess Incidence, Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Early-Stage, High-Risk HER2-Negative Breast Cancer in Alberta, Canada
Clinical Breast Cancer · 2025
DOI: 10.1016/j.clbc.2024.10.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Jan-Willem Henning und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Triple Negative Breast Neoplasms, Patient Acceptance of Health Care. Die Arbeit nennt 26 Literaturangaben. Gefördert von: AstraZeneca.
Abstract (Originalsprache)
BACKGROUND: Data are needed to improve the current understanding of the epidemiology of patients with high-risk, HER2-negative, early breast cancer (eBC) (hormone receptor positive [HR+]/HER2-negative BC and triple-negative BC [TNBC]). PATIENTS AND METHODS: This retrospective longitudinal cohort study used real-world, population-level data that included all individuals newly diagnosed with high-risk, HER2-negative eBC in Alberta, Canada, between 2010 and 2019. Data on treatment, laboratory results and pathology findings were collected through electronic health records and administrative databases. RESULTS: The annual cumulative incidence of high-risk, HER2-negative eBC ranged from 6% to 9% of all incident BC cases. Individuals with TNBC were more likely to be younger, had stage II disease, grade 3 histology and received systemic therapy at a community centre (P < .05) compared to individuals with HR+/HER2-negative eBC. Only 14% of individuals diagnosed in 2010-2017 underwent germline BRCA testing postdiagnosis. Neoadjuvant systemic therapy was given to 37% of individuals. Adjuvant systemic therapy use increased from 77% (2012-2015) to 84% (2019). The 5-year overall survival (OS) from initiation of adjuvant systemic therapy or date of surgery (for individuals who did not receive adjuvant systemic therapy) was 77% (95% CI: 75-79). OS was significantly worse among individuals who were older, had grade 3 histology, had stage III disease, or had nodal involvement (P < .05). OS among individuals with TNBC between 2016 and 2019 who initiated adjuvant capecitabine was markedly worse compared to the overall cohort (2-year OS: 70% vs. 89%). CONCLUSION: Outcomes analyses in this high-risk, HER2-negative eBC population suggest a continued unmet clinical need.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
- AstraZeneca Canada, Mississauga, Ontario, Canada.
- Department of Oncology, University of Calgary, Calgary, Alberta, Canada. Electronic address: winson.cheung@albertahealthservices.ca.
Förderung
- AstraZeneca
Zitieren
APA
Henning, J. W., Boyne, D. J., Brenner, D. R., Carbonell, C., Shokar, S., Granados, D. P., Parackal, A., & Cheung, W. Y. (2025). Real World Evidence Study to Assess Incidence, Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Early-Stage, High-Risk HER2-Negative Breast Cancer in Alberta, Canada. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.10.008
Vancouver
Henning JW, Boyne DJ, Brenner DR, Carbonell C, Shokar S, Granados DP, et al. Real World Evidence Study to Assess Incidence, Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Early-Stage, High-Risk HER2-Negative Breast Cancer in Alberta, Canada. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2024.10.008
BibTeX
@article{Henning2025,
author = {Henning, Jan-Willem and Boyne, Devon J and Brenner, Darren R and Carbonell, Chantelle and Shokar, Simran and Granados, Diana P and Parackal, Anna and Cheung, Winson Y},
title = {Real World Evidence Study to Assess Incidence, Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Early-Stage, High-Risk HER2-Negative Breast Cancer in Alberta, Canada},
journal = {Clinical Breast Cancer},
year = {2025},
doi = {10.1016/j.clbc.2024.10.008}
}
EUVIMED